A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...

Popular weight-loss medications including Ozempic and Wegovy contain a drug that seems to decrease cravings for food and ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound ... medications say coverage has a ...

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...